Hodgkin Disease Clinical Trial
Official title:
Phase II-study Using Ofatumumab and ESHAP Followed by Autologous Trasplant of Hemopoietic Precursors for the Treatment of Classic Hodgkin's Lymphoma on Relapse, Partial Response or Refractory to First Line Treatment
The aim of this study is to analyze the efficacy of O-ESHAP treatment for Hodgkin's lymphome
patients that have a first line chemotherapy treatment failure due to refractoriness,
partial response or relapsed.
In the same way, mortality, global survival and free-progression survival after O-ESHAP
treatment and TAPH will also analyzed.
In addition to the above:
- To asses the complete response rate after O-ESHAP.
- To asses the toxicity of O-ESHAP regimen
- To asses the stem cells mobilization capacity of O-ESHAP regimen
- To evaluate the final results of the whole procedure (O-ESHAP followed by high-dose
chemotherapy and ASCT): transplant-related mortality (TRM), overall survival (OS), and
progression free survival (PFS)
- To investigate the correlation between the overall response and CD20 expression by
tumoral cells.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02057185 -
Occupational Status and Hematological Disease
|
||
| Active, not recruiting |
NCT02979522 -
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00540007 -
Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT03755414 -
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
|
Phase 1 | |
| Recruiting |
NCT01676805 -
Tissue Collection for Studies of Lymph Cancer
|
||
| Completed |
NCT02378337 -
Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality
|
N/A | |
| Terminated |
NCT00916045 -
Pilot Study of Unrelated Cord Blood Transplantation
|
Phase 2 | |
| Completed |
NCT00534989 -
Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT
|
N/A | |
| Terminated |
NCT00393380 -
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
|
Phase 2 | |
| Completed |
NCT00062868 -
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
|
Phase 1 | |
| Completed |
NCT00388349 -
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
|
Phase 2 | |
| Recruiting |
NCT05255601 -
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01716806 -
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
|
Phase 2 | |
| Active, not recruiting |
NCT04998331 -
A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin
|
||
| Completed |
NCT02389101 -
Molecular and Whole-body MR Imaging in Lymphomas
|
N/A | |
| Completed |
NCT00871702 -
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease
|
Phase 1 | |
| Recruiting |
NCT02589548 -
Brazilian Prospective Hodgkin Lymphoma Registry
|
||
| Completed |
NCT00398411 -
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
|
Phase 3 | |
| Terminated |
NCT00514722 -
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies
|
N/A | |
| Terminated |
NCT00225173 -
Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease
|
Phase 2 |